Google DeepMind has published research demonstrating that its latest AlphaFold 3 model can predict not only protein structures but also how potential drug molecules will bind to those proteins, dramatically accelerating the drug discovery process for rare diseases.
The system has already identified promising drug candidates for three rare genetic disorders that currently have no approved treatments. Traditional drug discovery for these conditions would typically take 10 to 15 years; DeepMind's approach reduced the initial screening phase to just six months.
Several pharmaceutical companies have partnered with DeepMind to bring these candidates into clinical trials, with the first human studies expected to begin in early 2027.
